(TRDA) Entrada Therapeutics - Ratings and Ratios
Oligonucleotide, Enzyme, Antibody Therapies, EEV Peptides, Enzyme Replacement
TRDA EPS (Earnings per Share)
TRDA Revenue
Description: TRDA Entrada Therapeutics
Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biotechnology company that focuses on developing endosomal escape vehicle (EEV) therapeutics for treating multiple neuromuscular diseases. The companys EEV platform is designed to develop products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides, showcasing its innovative approach to addressing complex health issues.
The companys pipeline includes several promising therapeutic candidates, such as ENTR-601-44, which is in Phase 1 clinical trial for Duchenne muscular dystrophy, and VX-670, in Phase 1/2 clinical trial for myotonic dystrophy type 1. Additionally, Entrada Therapeutics has other preclinical candidates, including ENTR-601-45, ENTR-601-50, and ENTR-601-51, targeting Duchenne muscular dystrophy, and PTI-501 for mitochondrial neurogastrointestinal encephalomyopathy.
From a financial perspective, Entrada Therapeutics has a market capitalization of $268.71M USD, indicating a relatively small-cap company with potential for growth. The companys P/E ratio is 12.17, suggesting a relatively reasonable valuation compared to its earnings. However, the P/E Forward ratio is significantly higher at 3333.33, indicating high growth expectations. The Return on Equity (RoE) is 5.84%, which is a relatively modest return.
To further evaluate Entrada Therapeutics performance, we can examine additional KPIs. For instance, the companys research and development (R&D) expenses as a percentage of revenue can indicate its commitment to innovation. Additionally, the cash burn rate and cash reserves can provide insights into the companys financial sustainability. A closer look at the companys partnerships, such as the strategic collaboration with Vertex Pharmaceuticals Incorporated and the license agreement with Pierrepont Therapeutics, Inc., can also reveal the potential for future growth and revenue generation.
Overall, Entrada Therapeutics innovative EEV platform, promising pipeline, and strategic partnerships position the company for potential growth in the biotechnology sector. However, a more in-depth analysis of its financials and operational metrics is necessary to determine its investment potential.
TRDA Stock Overview
| Market Cap in USD | 205m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-10-29 |
TRDA Stock Ratings
| Growth Rating | -74.4% |
| Fundamental | 20.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -70.4% |
| Analyst Rating | 4.50 of 5 |
TRDA Dividends
Currently no dividends paidTRDA Growth Ratios
| Growth Correlation 3m | -89.1% |
| Growth Correlation 12m | -93.5% |
| Growth Correlation 5y | -11.9% |
| CAGR 5y | -29.66% |
| CAGR/Max DD 3y | -0.38 |
| CAGR/Mean DD 3y | -0.81 |
| Sharpe Ratio 12m | -1.54 |
| Alpha | 0.01 |
| Beta | 0.983 |
| Volatility | 64.63% |
| Current Volume | 218.9k |
| Average Volume 20d | 239.5k |
| Stop Loss | 4.8 (-6.3%) |
| Signal | -0.12 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-73.4m TTM) > 0 and > 6% of Revenue (6% = 4.77m TTM) |
| FCFTA -0.10 (>2.0%) and ΔFCFTA -33.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 439.6% (prev 168.6%; Δ 270.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.28 (>3.0%) and CFO -123.9m <= Net Income -73.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 18.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (41.3m) change vs 12m ago 16.42% (target <= -2.0% for YES) |
| Gross Margin 96.24% (prev 98.59%; Δ -2.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 15.42% (prev 41.14%; Δ -25.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 0.20
| (A) 0.78 = (Total Current Assets 369.1m - Total Current Liabilities 19.8m) / Total Assets 448.8m |
| (B) -0.42 = Retained Earnings (Balance) -189.8m / Total Assets 448.8m |
| (C) -0.10 = EBIT TTM -50.3m / Avg Total Assets 515.4m |
| (D) -2.73 = Book Value of Equity -189.4m / Total Liabilities 69.3m |
| Total Rating: 0.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 20.94
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -47.35% = -5.0 |
| 3. FCF Margin -56.26% = -7.50 |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda -1.16 = -2.50 |
| 6. ROIC - WACC (= -21.49)% = -12.50 |
| 7. RoE -17.81% = -2.50 |
| 8. Rev. Trend 38.38% = 2.88 |
| 9. EPS Trend 11.50% = 0.58 |
What is the price of TRDA shares?
Over the past week, the price has changed by -0.39%, over one month by -7.25%, over three months by -30.90% and over the past year by -64.81%.
Is Entrada Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TRDA is around 3.87 USD . This means that TRDA is currently overvalued and has a potential downside of -24.41%.
Is TRDA a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TRDA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.5 | 261.3% |
| Analysts Target Price | 18.5 | 261.3% |
| ValueRay Target Price | 4.4 | -15% |
Last update: 2025-09-04 04:49
TRDA Fundamental Data Overview
CCE Cash And Equivalents = 354.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 3333.3333
P/S = 2.5749
P/B = 0.5392
Beta = -0.126
Revenue TTM = 79.5m USD
EBIT TTM = -50.3m USD
EBITDA TTM = -47.4m USD
Long Term Debt = 49.5m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 5.46m USD (from shortTermDebt, last quarter)
Debt = 54.9m USD (Calculated: Short Term 5.46m + Long Term 49.5m)
Net Debt = -17.7m USD (from netDebt column, last quarter)
Enterprise Value = -94.4m USD (204.6m + Debt 54.9m - CCE 354.0m)
Interest Coverage Ratio = unknown (Ebit TTM -50.3m / Interest Expense TTM 0.0)
FCF Yield = -47.35% (FCF TTM -44.7m / Enterprise Value -94.4m)
FCF Margin = -56.26% (FCF TTM -44.7m / Revenue TTM 79.5m)
Net Margin = -92.30% (Net Income TTM -73.4m / Revenue TTM 79.5m)
Gross Margin = 96.24% ((Revenue TTM 79.5m - Cost of Revenue TTM 2.99m) / Revenue TTM)
Tobins Q-Ratio = 0.50 (Enterprise Value -94.4m / Book Value Of Equity -189.4m)
Interest Expense / Debt = 8.09% (Interest Expense 4.45m / Debt 54.9m)
Taxrate = 1.29% (859.0k / 66.5m)
NOPAT = -50.3m (EBIT -50.3m, no tax applied on loss)
Current Ratio = 18.64 (Total Current Assets 369.1m / Total Current Liabilities 19.8m)
Debt / Equity = 0.14 (Debt 54.9m / last Quarter total Stockholder Equity 379.5m)
Debt / EBITDA = -1.16 (Net Debt -17.7m / EBITDA -47.4m)
Debt / FCF = -1.23 (Debt 54.9m / FCF TTM -44.7m)
Total Stockholder Equity = 412.0m (last 4 quarters mean)
RoA = -16.34% (Net Income -73.4m, Total Assets 448.8m )
RoE = -17.81% (Net Income TTM -73.4m / Total Stockholder Equity 412.0m)
RoCE = -10.89% (Ebit -50.3m / (Equity 412.0m + L.T.Debt 49.5m))
RoIC = -12.20% (NOPAT -50.3m / Invested Capital 412.0m)
WACC = 9.29% (E(204.6m)/V(259.6m) * Re(9.64%)) + (D(54.9m)/V(259.6m) * Rd(8.09%) * (1-Tc(0.01)))
Shares Correlation 3-Years: 90.91 | Cagr: 2.56%
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -44.7m)
EPS Correlation: 11.50 | EPS CAGR: -41.10% | SUE: -0.31 | # QB: 0
Revenue Correlation: 38.38 | Revenue CAGR: 25.10% | SUE: N/A | # QB: None
Additional Sources for TRDA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle